Indomethacin-guided cancer selective prodrug conjugate activated by histone deacetylase and tumour-associated protease

Joo Hee Jang, Hoyeon Lee, Amit Sharma, Sang Min Lee, Tae Hoon Lee, Chulhun Kang, Jong Seung Kim

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

An indomethacin-guided drug delivery conjugate (IGDDC) has been designed by utilizing cancer associated elevated HDAC and CTSL activities as consecutive demasking ventures for drug activation. IGDDC exhibited preferential uptake by COX-2 positive cells both in vitro and ex vivo highlighting indomethacin's role in designing new cancer-specific drug delivery frameworks.

Original languageEnglish
Pages (from-to)9965-9968
Number of pages4
JournalChemical Communications
Volume52
Issue number64
DOIs
Publication statusPublished - 2016

Fingerprint

Histone Deacetylases
Prodrugs
Drug delivery
Indomethacin
Tumors
Peptide Hydrolases
Pharmaceutical Preparations
Neoplasms
Chemical activation
Cells

ASJC Scopus subject areas

  • Catalysis
  • Electronic, Optical and Magnetic Materials
  • Ceramics and Composites
  • Chemistry(all)
  • Surfaces, Coatings and Films
  • Metals and Alloys
  • Materials Chemistry

Cite this

Indomethacin-guided cancer selective prodrug conjugate activated by histone deacetylase and tumour-associated protease. / Jang, Joo Hee; Lee, Hoyeon; Sharma, Amit; Lee, Sang Min; Lee, Tae Hoon; Kang, Chulhun; Kim, Jong Seung.

In: Chemical Communications, Vol. 52, No. 64, 2016, p. 9965-9968.

Research output: Contribution to journalArticle

Jang, Joo Hee ; Lee, Hoyeon ; Sharma, Amit ; Lee, Sang Min ; Lee, Tae Hoon ; Kang, Chulhun ; Kim, Jong Seung. / Indomethacin-guided cancer selective prodrug conjugate activated by histone deacetylase and tumour-associated protease. In: Chemical Communications. 2016 ; Vol. 52, No. 64. pp. 9965-9968.
@article{d5d73e98e804461a933a2ad684bddcc3,
title = "Indomethacin-guided cancer selective prodrug conjugate activated by histone deacetylase and tumour-associated protease",
abstract = "An indomethacin-guided drug delivery conjugate (IGDDC) has been designed by utilizing cancer associated elevated HDAC and CTSL activities as consecutive demasking ventures for drug activation. IGDDC exhibited preferential uptake by COX-2 positive cells both in vitro and ex vivo highlighting indomethacin's role in designing new cancer-specific drug delivery frameworks.",
author = "Jang, {Joo Hee} and Hoyeon Lee and Amit Sharma and Lee, {Sang Min} and Lee, {Tae Hoon} and Chulhun Kang and Kim, {Jong Seung}",
year = "2016",
doi = "10.1039/c6cc04255d",
language = "English",
volume = "52",
pages = "9965--9968",
journal = "Chemical Communications",
issn = "1359-7345",
publisher = "Royal Society of Chemistry",
number = "64",

}

TY - JOUR

T1 - Indomethacin-guided cancer selective prodrug conjugate activated by histone deacetylase and tumour-associated protease

AU - Jang, Joo Hee

AU - Lee, Hoyeon

AU - Sharma, Amit

AU - Lee, Sang Min

AU - Lee, Tae Hoon

AU - Kang, Chulhun

AU - Kim, Jong Seung

PY - 2016

Y1 - 2016

N2 - An indomethacin-guided drug delivery conjugate (IGDDC) has been designed by utilizing cancer associated elevated HDAC and CTSL activities as consecutive demasking ventures for drug activation. IGDDC exhibited preferential uptake by COX-2 positive cells both in vitro and ex vivo highlighting indomethacin's role in designing new cancer-specific drug delivery frameworks.

AB - An indomethacin-guided drug delivery conjugate (IGDDC) has been designed by utilizing cancer associated elevated HDAC and CTSL activities as consecutive demasking ventures for drug activation. IGDDC exhibited preferential uptake by COX-2 positive cells both in vitro and ex vivo highlighting indomethacin's role in designing new cancer-specific drug delivery frameworks.

UR - http://www.scopus.com/inward/record.url?scp=84982693879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982693879&partnerID=8YFLogxK

U2 - 10.1039/c6cc04255d

DO - 10.1039/c6cc04255d

M3 - Article

VL - 52

SP - 9965

EP - 9968

JO - Chemical Communications

JF - Chemical Communications

SN - 1359-7345

IS - 64

ER -